8-K current report · filed Nov 3, 2026

ARVINAS, INC. (ARVN) 8-K Current Report: November 3, 2026

Item 2.02Item 7.01Item EX-99.2Item EX-99.1ARVN overview

Short answer

ARVINAS, INC. (ARVN) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026.

ARVINAS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Corporate update accompanying quarterly results
  • Full results and management commentary in Exhibit 99.1

Item 7.01 · Regulation FD Disclosure

  • Updated corporate presentation dated November 3, 2026
  • Exhibit 99.2 contains investor materials for review
  • Presentation availability may provide updated company strategy and investor messaging

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $0.5M versus $41.9M, reflecting the loss of prior Pfizer and Novartis milestone revenue
  • Cash, restricted cash and marketable securities $558.9M, funding planned operations into 2H 2028
  • Q3 net loss $53.9M, or $0.82 per share, versus $35.1M loss and $0.48 per share in Q3 2025
  • ARV-6723 entered Phase 1/2 dosing, expanding Arvinas’ pipeline into immuno-oncology and pembrolizumab combinations
  • ARV-102 data linked improved eye movement with reduced LRRK2 CSF biomarkers, supporting planned PSP Phase 1b trials in Europe and the UK

Item EX-99.2 · Exhibit EX-99.2

  • Investor presentation highlights ARV-393 Phase 1 enrollment in relapsed/refractory NHL, with initial monotherapy data targeted for 4Q 2026
  • Updated ARV-393 monotherapy and glofitamab-combination data targeted for mid-2027, creating near-term clinical catalysts
  • ARV-393’s oral BCL6 degradation strategy targets B-cell and T-cell lymphomas, including high-unmet-need AITL
  • Arvinas reports cash runway into 2H 2028, reducing near-term financing pressure
  • Vepdegestrant received FDA approval May 1, 2026 and was out-licensed to Rigel, supporting future milestone and royalty potential

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ARVINAS, INC. 8-K filings

Get the next ARVN 8-K as it lands

Follow ARVN for push alerts, or ask the research agent what this filing means.